Skip to content

Performance of a new real-time continuous glucose monitoring system: a validation study of the idi-CGM in type 1 diabetes

Performance of a new real-time continuous glucose monitoring system: a validation study of the idi-CGM in type 1 diabetes - Validation MySensible idi-CGM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56615
Enrollment
15
Registered
2024-02-22
Start date
2026-10-15
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Patients wear a new device that measures glucose.

Sponsors

Isala Klinieken
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - presence of type 1 DM; - age between 18 and 75 years old.

Exclusion criteria

Exclusion criteria: - A history of allergies towards (microneedle) patch substances/adhesive; - The inability to understand the Dutch language; - Oral of injected steroid using within the past 3 months - Pregnancy or planned pregnancy - Uncontrolled thyroid disease or hypertension - Poor visual acuity - Inability or unwillingness to meet the protocol requirements - Any severe or uncontrolled medical or psychological condition which, in the opinion of the investigator, would compromise the ability to meet protocol requirements.

Design outcomes

Primary

MeasureTime frame
Primary outcome is the accuracy of the idi-CGM compared to Contour Plus Blue strip capillary measurement results during the 14-day study period.

Secondary

MeasureTime frame
Secondary outcomes include (i) accuracy of the idi-CGM compared to the Dexcom G6 rt-CGM during the 14-day study period, (ii) accuracy of the idi-CGM during the standardized meal test and (iii) usability and satisfaction with the idi-CGM. Accuracy will (primarily) be analysed as according to the guidelines for Integrated Continuous Glucose Monitoring Approvals (Class II-510(K), (Parkes) error grid-, bias (including MARD), correlation, stability and Bland- Altman analysis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)